Randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without concurrent and consolidation bevacizumab (NSC #704865, IND #7921) in the treatment of primary stage II, III or IV epithelial ovarian, peritoneal or fallopian tube cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT01167712?term=GOG-0262&rank=1

2. Intervention

   Carboplatin

3. Intervention

   Paclitaxel

4. Intervention

   Bevacizumab

5. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

6. Resource Description

   Giving bevacizumab together with combination chemotherapy may kill more tumor cells. It is not yet known whether giving paclitaxel once every three weeks is more effective than giving paclitaxel once a week. This randomized phase III clinical trial is studying two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.

7. Contact

   Berenberg, Jeffrey

8. PI

   Berenberg, Jeffrey

9. Topic

   ovarian cancer

10. Study Population

    Females at least 18 years old, no more than 12 weeks since diagnostic/staging surgery, no previous cancer treatment that contraindicates study treatment, and no previous targeted therapy or hormone therapy for management of ovarian epithelial, fallopian tube, or primary peritoneal cancer.

11. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=681448&version=healthprofessional

12. Funded by

    Gynecologic Oncology Group

13. Phase

    Phase 3 clinical trial

14. Performed by

    Clinical Protocol & Data Management Shared Resource